{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:53:22Z","timestamp":1789412002877,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T00:00:00Z","timestamp":1478649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ebiomedicine.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.ebiom.2016.11.016","type":"journal-article","created":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T12:46:54Z","timestamp":1478782014000},"page":"168-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":148,"special_numbering":"C","title":["Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration"],"prefix":"10.1016","volume":"14","author":[{"given":"Ian J.","family":"Constable","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora M.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chooi-May","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron L.","family":"Magno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariapia A.","family":"Degli-Esposti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyn A.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian L.","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel B.","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Blumenkranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth P.","family":"Rakoczy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2016.11.016_bb0005","doi-asserted-by":"crossref","first-page":"120ra15","DOI":"10.1126\/scitranslmed.3002865","article-title":"AAV2 gene therapy readministration in three adults with congenital blindness","volume":"4","author":"Bennett","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0010","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0161-6420(85)34015-0","article-title":"Long-term diabetic vitrectomy results. Report of 10year follow-up","volume":"92","author":"Blankenship","year":"1985","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ebiom.2016.11.016_bb0015","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1471-4914(02)02362-6","article-title":"PEDF: anti-angiogenic guardian of ocular function","volume":"8","author":"Bouck","year":"2002","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0020","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States","volume":"122","author":"Congdon","year":"2004","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0025","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"CATT Research Group","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0030","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ebiom.2016.11.016_bb0035","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0040","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"IVAN Study Investigators","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ebiom.2016.11.016_bb0045","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ajo.2007.08.012","article-title":"Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results","volume":"144","author":"Kaiser","year":"2007","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0050","doi-asserted-by":"crossref","first-page":"10705","DOI":"10.1073\/pnas.90.22.10705","article-title":"Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor","volume":"90","author":"Kendall","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0055","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/bjo.81.2.154","article-title":"Increased expression of angiogenic growth factors in age-related maculopathy","volume":"81","author":"Kliffen","year":"1997","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0060","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1089\/104303401750270959","article-title":"Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization","volume":"12","author":"Lai","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0065","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/gt.2011.169","article-title":"Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates","volume":"19","author":"Lai","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0070","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1167\/iovs.08-3253","article-title":"rAAV.sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vector","volume":"50","author":"Lai","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0075","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.ymthe.2005.04.022","article-title":"Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys","volume":"12","author":"Lai","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0080","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/978-1-4615-0067-4_57","article-title":"Virus-mediated secretion gene therapy \u2013 a potential treatment for ocular neovascularization","volume":"533","author":"Lai","year":"2003","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0085","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/sj.gt.3301695","article-title":"Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy","volume":"9","author":"Lai","year":"2002","journal-title":"Gene Ther."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0090","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study","volume":"148","author":"Lalwani","year":"2009","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0095","first-page":"1760","article-title":"Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential","volume":"14","author":"Li","year":"2008","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0100","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00324","article-title":"Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1","volume":"2","author":"Luo","year":"2013","journal-title":"Elife"},{"key":"10.1016\/j.ebiom.2016.11.016_bb0105","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for Leber's congenital amaurosis","volume":"358","author":"Maguire","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0110","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nature15818","article-title":"Gene therapy returns to centre stage","volume":"526","author":"Naldini","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2016.11.016_bb0115","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/jcp.10026","article-title":"Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF","volume":"189","author":"Ohno-Matsui","year":"2001","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0120","doi-asserted-by":"crossref","first-page":"a017285","DOI":"10.1101\/cshperspect.a017285","article-title":"The status of RPE65 Gene therapy trials: safety and efficacy","volume":"5","author":"Pierce","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)00345-1","article-title":"Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1year follow-up of a phase 1 randomised clinical trial","author":"Rakoczy","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2016.11.016_bb0130","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0135","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ebiom.2016.11.016_bb0140","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/mt.2009.277","article-title":"Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5years after vector administration","volume":"18","author":"Simonelli","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0145","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ophtha.2012.11.048","article-title":"Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital amaurosis type 2","volume":"120","author":"Testa","year":"2013","journal-title":"Ophthalmology"},{"issue":"92\u2013100","key":"10.1016\/j.ebiom.2016.11.016_bb0150","first-page":"e1","article-title":"The reduction of serum soluble Flt-1 in patients with neovascular age-related macular degeneration","volume":"159","author":"Uehara","year":"2015","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.ebiom.2016.11.016_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061396","article-title":"AAV-mediated gene therapy for choroideremia: preclinical studies in personalized models","volume":"8","author":"Vasireddy","year":"2013","journal-title":"PLoS One"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396416305205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396416305205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T17:20:17Z","timestamp":1536254417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396416305205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":31,"alternative-id":["S2352396416305205"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2016.11.016","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727000237.793530518","asserted-by":"object"}]},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2016.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}